The regulatory peptide pidotimod facilitates M2 macrophage polarization and its function

Amino Acids

Volumn 46, Issue 5, 2014, Pages 1177-1185

  Hu, Shenglan ^a   Fu, Xudong ^b   Fu, Aikun ^a   Du, Wei ^a   Ji, Jian ^c   Li, Weifen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

^c INSTITUTE OF ANIMAL SCIENCE   (China)

Author keywords

Cell migration; M2 macrophage; Pidotimod; Polarization; Wound healing

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE; PIDOTIMOD; PYROGLUTAMIC ACID; THIAZOLIDINE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL POLARITY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE;

ANIMALS; BIOLOGICAL MARKERS; CELL POLARITY; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; PEPTIDES; PYRROLIDONECARBOXYLIC ACID; THIAZOLIDINES;

EID: 84898894928     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1676-4     Document Type: Article

References (43)

1. Auteri A, Pasqui AL, Bruni F et al (1992) Effect of pidotimod, a new immunostimulating agent, on some aspects of immune response. In vitro study. Pharmacol Res 26(Suppl 2):196-197
2. Benoit M, Desnues B, Mege JL (2008) Macrophage polarization in bacterial infections. J Immunol 181:3733-3739
3. Bronte V, Zanovello P (2005) Regulation of immune responses by l-Arginine metabolism. Nat Rev Immunol 5:641-654
4. Careddu P, Mei V, Venturoli V, Corsini A (1994) Pidotimod in the treatment of recurrent respiratory infections in paediatric patients. Arzneimittelforschung 44:1485-1489
5. Coppi G, Barchielli M (1991) Simple high-performance liquid chromatographic method for the determination of PGT/1A, a new immunostimulating drug, in biological fluids. J Chromatogr 563:385-391
6. Coppi G, Manzardo S (1994) Experimental immunological screening tests on pidotimod. Arzneimittelforschung 44:1411-1416
7. di Marco R, Condorelli F, Girardello R et al (1992) Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator pidotimod. Scand J Infect Dis 24:821-823
8. Edwards JP, Zhang X, Frauwirth KA et al (2006) Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 80:1298-1307
9. Giagulli C, Noerder M, Avolio M et al (2009) Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Int Immunopharmacol 9:1366-1373
10. Goerdt S, Orfanos CE (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10:137-142
11. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35
12. Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593-604
13. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953-964
14. Heilbronn LK, Campbell LV (2008) Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 14:1225-1230
15. Hesse M, Modolell M, La Flamme AC et al (2001) Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of l-Arginine metabolism. J Immunol 167:6533-6544
16. Hu X, Zhang W, Wang L et al (2012) The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod (PTD). Hum Vaccin Immunother 8:1250-1258
17. Ji J, Hu SL, Cui ZW et al (2013) Probiotic Bacillus amyloliquefaciens mediate M1 macrophage polarization in mouse bone marrow-derived macrophages. Arch Microbiol 195:349-356
18. Jiang J, Grieb B, Thyagarajan A et al (2008) Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med 21:577-584
19. Kang K, Reilly SM, Karabacak V et al (2008) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7:485-495
20. Kreider T, Anthony RM, Urban JJ et al (2007) Alternatively activated macrophages in helminth infections. Curr Opin Immunol 19:448-453
21. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329-333
22. Mantovani A, Sozzani S, Locati M et al (2002) Macrophage polarization: tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555
23. Mantovani A, Sica A, Sozzani S et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686
24. Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. Immunity 23:344-346
25. Manzardo S, Falcone A, Pinzetta A et al (1994) General pharmacology of pidotimod and testing for drug interactions. Arzneimittelforschung 44:1441-1447
26. Martinez FO, Helming L, Gordon S (2009) Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27:451-483
27. Mege JL, Mehraj V, Capo C (2011) Macrophage polarization and bacterial infections. Curr Opin Infect Dis 24:230-234
28. Migliorati G, D'Adamio L, Coppi G et al (1992) Pidotimod stimulates natural killer cell activity and inhibits thymocyte cell death. Immunopharmacol Immunotoxicol 14:737-748
29. Migliorati G, Nicoletti I, Riccardi C (1994) Immunomodulating activity of pidotimod. Arzneimittelforschung 44:1421-1424
30. Mikita T, Campbell D, Wu P et al (1996) Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol 16:5811-5820
31. Mookherjee N, Brown KL, Bowdish DM et al (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176:2455-2464
32. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73:209-212
33. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969
34. Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723-737
35. Nair MG, Gallagher IJ, Taylor MD et al (2005) Chitinase and Fizz family members are a generalized feature of nematode infection with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. Infect Immun 73:385-394
36. Pollard JW (2009) Trophic macrophages in development and disease. Nat Rev Immunol 9:259-270
37. Raes G, De Baetselier P, Noel W et al (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol 71:597-602
38. Riboldi P, Gerosa M, Meroni PL (2009) Pidotimod: a reappraisal. Int J Immunopathol Pharmacol 22:255-262
39. Rolls A, Shechter R, London A et al (2008) Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med 5:e171
40. Saccani A, Schioppa T, Porta C et al (2006) p50 nuclear factor-kappaB overexpression in tumor-Associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66:11432-11440
41. Satoh T, Takeuchi O, Vandenbon A et al (2010) The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 11:936-944
42. Soehnlein O, Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10:427-439
43. Stein M, Keshav S, Harris N et al (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176:287-292